Shots:
- ACEA to receive up to ~$38M in shares of Sorrento common stock, $450M as additional payments upon the achievement of clinical & sales milestones along with 5 – 10% royalties based on annual sales of each product. The acquisition is expected to close in Q2’ 21
- The acquisition includes Abivertinib, AC0058, AC0939, and ACEA’s compound library of small molecules which has the potential for numerous human disease indications, including NSCLC, BCL, SL, RA, MS and viral infections
- The acquisition will also include ACEA’s state of the art cGMP facility located in Quzhou, China which has the capacity to manufacture up to 5,000 kg/year of APIs and 50,000,000 capsules of final drug product
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Biocom
The post Sorrento to Acquire ACEA Therapeutics for ~$488M first appeared on PharmaShots.
